ACR Appropriateness Criteria®: Local-Regional Therapy for Resectable Oropharyngeal Squamous Cell Carcinomas

Current Problems in Cancer

Volumn 34, Issue 3, 2010, Pages 175-192

  Quon, Harry ^a   Yom, Sue S ^a   Garg, Madhur Kumar ^a   Lawson, Joshua ^a   McDonald, Mark W ^a   Ridge, John A ^a   Saba, Nabil ^a   Salama, Joseph ^a   Smith, Richard ^a   Yeung, Anamaria Reyna ^a   Beitler, Jonathan J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LOCAL THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OROPHARYNX CARCINOMA; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; GUIDELINE ADHERENCE; HUMANS; OROPHARYNGEAL NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE;

EID: 77953091411     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2010.04.004     Document Type: Article

References (71)

1. Caudell J.J., Schaner P.E., Meredith R.F., et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 73 (2009) 410-415
2. Langendijk J.A., Doornaert P., Rietveld D.H., et al. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 90 (2009) 189-195
3. Machtay M., Moughan J., Trotti A., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26 (2008) 3582-3589
4. Langendijk J.A., Doornaert P., Verdonck-de Leeuw I.M., et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26 (2008) 3770-3776
5. Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31 (2004) 744-754
6. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000) 709-720
7. Ernster J.A., Sciotto C.G., O'Brien M.M., et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 117 (2007) 2115-2128
8. Chien C.Y., Su C.Y., Fang F.M., et al. Lower prevalence but favorable survival for human papillomavirus-related squamous cell carcinoma of tonsil in Taiwan. Oral Oncol 44 (2008) 174-179
9. Fischer C.A., Zlobec I., Green E., et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?. Int J Cancer 126 (2010) 1256-1262
10. Hannisdal K., Schjolberg A., De Angelis P.M., et al. Human papillomavirus (HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol (2009) 1-7
11. Klozar J., Kratochvil V., Salakova M., et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol 265 Suppl 1 (2008) S75-S82
12. Klussmann J.P., Mooren J.J., Lehnen M., et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 15 (2009) 1779-1786
13. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24 (2006) 5630-5636
14. Straetmans J.M., Olthof N., Mooren J.J., et al. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 119 (2009) 1951-1957
15. Weinberger P.M., Yu Z., Haffty B.G., et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24 (2006) 736-747
16. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100 (2008) 261-269
17. Gillison M.L., Harris J., Westra W.H., et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. Asco Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 27 (2009) 6003
18. Rischin D., Young R., Fisher R., et al. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. Asco Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 27 (2009) 6004
19. Settle K., Posner M.R., Schumaker L.M., et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila Pa) 2 (2009) 776-781
20. Worden F.P., Kumar B., Lee J.S., et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26 (2008) 3138-3146
21. Kies M.S., Holsinger F.C., and Lee J.J. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a Phase II Prospective Trial. J Clin Oncol 28 (2010) 8-14
22. Lassen P., Eriksen J.G., Hamilton-Dutoit S., et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 94 (2010) 30-35
23. Ragin C.C., and Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121 (2007) 1813-1820
24. Hafkamp H.C., Manni J.J., Haesevoets A., et al. Marked differences in survival rate between smokers and nonsmokers with HPV sixteen-associated tonsillar carcinomas. Int J Cancer 122 (2008) 2656-2664
25. Worden F.P., Hooton J., Lee J.J., et al. Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP). J Clin Oncol 27 (2009) 6001
26. Holsinger F.C., McWhorter A.J., Menard M., et al. Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region. I. Technique, complications, and functional results. Arch Otolaryngol Head Neck Surg 131 (2005) 583-591
27. Moore E.J., Henstrom D.K., Olsen K.D., et al. Transoral resection of tonsillar squamous cell carcinoma. Laryngoscope 119 (2009) 508-515
28. Weinstein GS, O'Malley BW Jr, Cohen MA, et al. Transoral robotic surgery (TORS) for advanced oropharyngeal squamous cell carcinoma: oncologic and functional results. Paper presented at Am Academy of Otolaryngol Head and Neck Society, 2009.
29. Harrison L.B., Zelefsky M.J., Pfister D.G., et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 19 (1997) 169-175
30. Horwitz E.M., Frazier A.J., Martinez A.A., et al. Excellent functional outcome in patients with squamous cell carcinoma of the base of tongue treated with external irradiation and interstitial iodine one hundred and twenty-five boost. Cancer 78 (1996) 948-957
31. Levendag P.C., Teguh D.N., Voet P., et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85 (2007) 64-73
32. Pernot M., Hoffstetter S., Peiffert D., et al. Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation. Otolaryngol Head Neck Surg 115 (1996) 519-526
33. Petruson K., Mercke C., Lundberg L.M., et al. Longitudinal evaluation of patients with cancer in the oral tongue, tonsils, or base of tongue-does interstitial radiation dose affect quality of life?. Brachytherapy 4 (2005) 271-277
34. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
35. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006) 843-854
36. Pignon J.P., le Maitre A., Maillard E., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on ninety-three randomised trials and 17,346 patients. Radiother Oncol 92 (2009) 4-14
37. Nguyen L.N., and Ang K.K. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol 3 (2002) 693-701
38. Moreno-Jimenez M., Valero J., Lopez-Picazo J.M., et al. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: Comparison of two different schedules. Am J Clin Oncol 33 (2010) 137-143
39. Lauve A., Morris M., Schmidt-Ullrich R., et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II-clinical results. Int J Radiat Oncol Biol Phys 60 (2004) 374-387
40. Mell L.K., Mehrotra A.K., and Mundt A.J. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer 104 (2005) 1296-1303
41. Eisbruch A., Ship J.A., Dawson L.A., et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 27 (2003) 832-837
42. Lee N., Xia P., Fischbein N.J., et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 57 (2003) 49-60
43. Saarilahti K., Kouri M., Collan J., et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 74 (2005) 251-258
44. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 49 (2001) 907-916
45. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66 (2006) 981-991
46. Gregoire V., De Neve W., Eisbruch A., et al. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 12 (2007) 555-564
47. Mendenhall W.M., Amdur R.J., and Palta J.R. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 24 (2006) 2618-2623
48. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
49. Al-Sarraf M., leBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
50. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
51. Chan A.T., Teo P.M., Ngan R.K., et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 (2002) 2038-2044
52. Chen Y., Liu M.Z., Liang S.B., et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 71 (2008) 1356-1364
53. Uygun K., Bilici A., Karagol H., et al. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 64 (2009) 601-605
54. Ho K.F., Swindell R., and Brammer C.V. Dose intensity comparison between weekly and 3-weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 47 (2008) 1513-1518
55. Rades D., Fehlauer F., Sheikh-Sarraf M., et al. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage. III/IV head and neck cancer. Head Neck 30 (2008) 235-241
56. Beckmann G.K., Hoppe F., Pfreundner L., et al. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27 (2005) 36-43
57. 2 in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol 185 (2009) 682-688
58. Traynor A.M., Richards G.M., Hartig G.K., et al. Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck 32 (2010) 599-606
59. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11 (2010) 21-28
60. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
61. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
62. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
63. Hitt R., Grau J.J., Lopez-Pousa A., et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/ 5-FU or docetaxel/cisplatin/ 5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 27 (2009) 6009
64. Paccagnella A., Buffoli A., Koussis H., et al. Concomitant chemoradiotherapy (CT/RT) vs neoadjuvant chemotherapy with docetaxel/cispaltin/ 5-fluorouracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study (Meeting Abstracts). J Clin Oncol 26 (2008) 6000
65. Grant D.G., Salassa J.R., Hinni M.L., et al. Carcinoma of the tongue base treated by transoral laser microsurgery. Part I. Untreated tumors: a prospective analysis of oncologic and functional outcomes. Laryngoscope 116 (2006) 2150-2155
66. Laccourreye O., Hans S., Menard M., et al. Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region. II. An analysis of the incidence, related variables, and consequences of local recurrence. Arch Otolaryngol Head Neck Surg 131 (2005) 592-599
67. Steiner W., Fierek O., Ambrosch P., et al. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 129 (2003) 36-43
68. Weinstein G.S., O'Malley Jr. B.W., Snyder W., et al. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 133 (2007) 1220-1226
69. Peters L.J., Goepfert H., Ang K.K., et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 26 (1993) 3-11
70. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
71. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944